Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib

详细信息    查看全文

• 作者：Wei Xu ; Yunyan Wei ; Shuangshuang Wu ; Yun Wang ; Zhen Wang ; Yu Sun…
• 关键词：TAZ ; EGFR ; EMT ; Gefitinib ; Lung adenocarcinoma
• 刊名：Cell & Bioscience
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：5
• 期：1
• 全文大小：1,743 KB
• 刊物主题：Cell Biology; Microbiology;
• 出版者：BioMed Central
• ISSN：2045-3701

文摘

Background The T790M mutation of epithelial growth factor receptor (EGFR) is a major cause of the acquired resistance to EGFR tyrosine kinase inhibitor (EGFR-TKIs) treatment for lung cancer patients. The Hippo pathway effector, TAZ, has emerged as a key player in organ growth and tumorigenesis, including lung cancer.